DNA损伤修复缺陷对镭-223治疗转移性去势抵抗性前列腺癌疗效及总生存的影响
DDR+患者总生存显著延长(中位36.3 vs 17.0个月;HR 2.29;P=0.01),且更常完成镭-223治疗(79% vs 47%;P=0.05)。
要点
- DDR突变见于30%的镭-223治疗患者,常见ATM、BRCA2、CDK12。
- DDR+患者总生存显著优于DDR-患者(中位36.3 vs 17.0个月)。
- DDR+患者镭-223完成率更高(79% vs 47%),但生化反应无差异。
核心结论
- 携带DDR基因突变的患者接受镭-223治疗总生存显著延长,且更常完成治疗。
- 该发现需前瞻性研究确认,并支持在DDR缺陷患者中应用镭-223等基因毒性药物的策略。
研究设计与样本
- 按DDR基因存在(DDR+)或不存在(DDR-)致病性体细胞或胚系突变分组。
主要发现
- DDR+患者中位总生存36.3个月,DDR-患者17.0个月(HR 2.29;P=0.01)。
- DDR+与DDR-患者的中位至ALP进展时间分别为6.9 vs 5.8个月(HR=1.48;P=0.15),至后续系统治疗时间分别为8.9 vs 7.3个月(HR=1.58;P=0.08)。
- DDR+患者完成镭-223治疗的比例更高(79% vs 47%;P=0.05),生化反应无差异。
临床怎么用
- 对接受镭-223治疗的mCRPC患者,可考虑检测DDR基因突变以辅助预后判断和治疗决策。
- DDR突变患者可能从镭-223治疗中获得更长的总生存和更高的治疗完成率。
局限性
- 结果需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radium-223 is a targeted alpha radiation therapy for metastatic castration-resistant prostate cancer. DNA damage repair (DDR) defective prostate cancers, specifically genetic aberrations leading to homologous recombination deficiency (HRD), accumulate irreparable DNA damage following genotoxic treatment. This retrospective study assessed DDR mutation status in patients treated with radium-223, investigating their association with efficacy and overall survival (OS). PATIENTS AND METHODS: Included patients were treated with radium-223 and had results from primary or metastatic tumour tissue of a comprehensive next-generation sequencing panel of DDR genes, including canonical HRD genes. Patients were grouped by presence (DDR+) or absence (DDR-) of pathogenic somatic or germline aberrations in DDR genes. We evaluated OS, time to ALP progression (TAP), time to initiation of subsequent systemic therapy (TST) and biochemical responses between DDR groups. RESULTS: Ninety-three patients were included. Twenty-eight (30%) patients had DDR mutations, most frequently in ATM (8.6%), BRCA2 (7.5%) and CDK12 (4.3%) genes. DDR+ patients showed prolonged OS (median 36.3 versus 17.0 months; HR 2.29; P = 0.01). Median TAP and TST in the DDR+ and DDR- patients was 6.9 versus5.8 months (HR = 1.48; P = 0.15), and 8.9 versus7.3 months (HR = 1.58; P = 0.08), respectively. DDR+ patients more frequently completed radium-223 therapy (79% versus 47%; P = 0.05). No difference in biochemical responses were seen. CONCLUSION: Patients harbouring DDR aberrations showed significant OS benefit, and more commonly completed radium-223 therapy. These findings need prospective confirmation and support strategies of genotoxic agents such as radium-223 in patients harbouring DDR defects.
引用
- van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, et al. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. Eur J Cancer. 2020. PMID: 32634759. doi:10.1016/j.ejca.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。